Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas, Ángela; Sánchez‐Torrijos, Yolanda; Gil‐Gómez, Antonio; Liu, Changhai; Rodríguez-Rivas, Clara; Ferrer, María Teresa Martínez; Romero–Gómez, Manuel

doi:10.20517/2394-5079.2018.60

Cited by 9 publications

(10 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results go along with Rojas et al (5) who demonstrated that AFP and GPC3 combination carried higher sensitivity and specificity (98.5% and 97.8%, respectively). Moreover, GPC3 was detected in around one third of confirmed HCC patients with normal serum AFP.…”

Section: Discussionsupporting

confidence: 84%

“…Glypican-3 (GPC3) is one of the glypican family of glycosyl-phosphatidylinositol-anchored cell-surface heparan-sulfate proteoglycans. The levels of which are significantly elevated in HCC patients (5) . Trials showed that serum GPC3 is an early sensitive and specific biomarker for initial laboratory diagnosis of HCC and for detection of recurrence (12) .…”

Section: Discussionmentioning

confidence: 95%

“…Glypican-3 (GPC3) is a glycosyl-phosphatidyl inositol anchored cell surface heparan sulphate proteoglycan that belongs to the glypican family. Because GPC3 is not seen in healthy liver tissue and increases significantly in patients with HCC, it has been discovered as a useful tumor marker for HCC detection (5) . Several studies on the utility of serum GPC3 as a marker for the initial diagnosis of HCC and detection of recurrence following liver transplantation have demonstrated its sensitivity and specificity (6) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Value of Glypican-3 as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma before and after Treatment. A Prospective Study

Isaac¹,

Badawy²,

Mohamed³

et al. 2021

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma is a highly prevalent tumor globally and the world's second leading cause of cancer-related deaths. Glypican-3, a heparan sulfate proteoglycan expressed on the surface of HCC cells, has emerged as a new molecule with a strong link to occurrence and progression of HCC. Objective: This study was done to determine the role of Glypican-3 in diagnosis of HCC and its prognostic value following different treatment modalities. Patients and methods: The study included thirty patients with liver cirrhosis and HCC on top, and thirty patients with liver cirrhosis without HCC. Standard laboratory investigations, abdominal ultrasound and triphasic computed tomography were done for all patients. Serum alpha fetoprotein and Glypican-3 were measured in all patients before and one month after different treatment modalities. Results: Glypican-3 was significantly higher in HCC group (2.28 ± 0.97) in comparison to cirrhosis group (0.56 ± 0.31) with P-value <0.001. Glypican-3 level was higher in larger sized lesions with p value 0.023, one month after treatment with different modalities, Glypican-3 declined significantly (from 2.28 ± 0.97 to 1.44 ± 0.93) with p value <0.001. At a cutoff point of > 1.1 ng/ml Glypican-3 has 93.3% sensitivity, 96.67% specificity, 96.6% PPV and 93.5% NPV for detection of HCC. Conclusion: Glypican-3 can be a valuable diagnostic marker for HCC diagnosis and prognosis after various treatment modalities and may be complementary to alpha fetoprotein increasing overall sensitivity of HCC detection.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Value of Glypican-3 as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma before and after Treatment. A Prospective Study

Isaac¹,

Badawy²,

Mohamed³

et al. 2021

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…47.73%. These values were in line with previous studies conducted on AFP's sensitivity which are usually in the range of 41% to 84%(10,(28)(29)(30) which is a very broad range due to different Aqsa Ahmed et al,…”

supporting

confidence: 92%

“…the MedCalc diagnostic test evaluation calculator, different metrics linked to a biomarker's diagnostic capacity were computed after the number of True positives, True negatives, False positives, and False negatives were determined. The specificity was found to be 95.45 percent, while the sensitivity was 77.27 percent which are excellent values for a biomarker of HCC, and these values are far better than reported for AFP(29,30). The test's accuracy was determined to be 86.36 percent which further enhances confidence in the diagnostic ability of this candidate biomarker.…”

mentioning

confidence: 73%

Validation of Protein Biomarker Candidates for Diagnosis of HBV induced HCC

Ahmed¹,

Al‐Ansi²,

Basharat³

et al. 2022

IJAAST

View full text Add to dashboard Cite

Hepatocellular carcinoma is a major contributor to the global cancer burden. It affects millions of people in Pakistan on a yearly basis. Furthermore, HCC is linked to viral infections Hepatitis B and C, which account for roughly 87 percent of HCC cases in Pakistan. HCC is identified using imaging techniques such as MRI, Ultrasound, and histology, which have radiation hazards and frequently need expensive healthcare systems that are less available in most of the developing countries. Novel HCC biomarkers are being developed as part of a large research project aimed at detecting the disease early. These include the creation of biomarkers based on HCC patients' transcriptome and proteomic profiles. Circulating proteins, which are easily detected in body fluids, including blood serum, may thus provide an opportunity for the development of HCC biomarkers. Blood-based serum biomarkers must be developed for easy, non-invasive, and early detection of HCC. In conjunction with imaging techniques, alpha-fetoprotein (AFP) has been used to detect HCC, although it has little clinical usefulness. Also, the reported AFP negative results make its utility meager. Multiple circulating proteins have been studied as biomarker possibilities for HCC diagnosis in recent years. In this study, Blood serum was used to validate three novel protein biomarker candidates to detect HBV induced HCC that had previously been predicted using a bioinformatics methodology. Proteins named C6, C8A and C8B were measured in the serum of 22 HCC patients infected with HBV in Pakistani population and compared to AFP levels using quantitative ELISA. C8A possesses considerable biomarker potential, with 95.45 percent specificity and 77.27% sensitivity with 0.933 Area Under the Curve (AUC), whereas C6 and C8B showed poor biomarker potential. Hence, C8A demonstrated great promise as a circulating blood-based protein biomarker for HBV induced HCC diagnosis.

show abstract

Novel hepatocellular carcinomas (HCC) Subtype-Specific Biomarkers

Croft,

Quintanar,

Gao

et al. 2023

Preprint

View full text Add to dashboard Cite

IntroductionHepatocellular carcinoma (HCC), the most common form of liver cancer, is a global health concern and a leading cause of cancer-related deaths. HCC accounts for a significant portion of liver cancers and has low survival rates of 5% to 30%, especially for HCC patients with a survival rate of 15%. Early detection is challenging due to the absence of symptoms in the early stages. The complexity and molecular diversity of HCC contribute to its poor prognosis. Understanding its molecular subtypes and mechanisms is crucial for improved management.MethodsThe study utilized publicly available data to investigate the potential diagnostic and prognostic biomarkers for hepatocellular carcinoma (HCC) based on their transcript per million (TPM) expression levels. A dataset of 407 HCC patient profiles was analyzed for survival trends and gene expression patterns.ResultsThrough a comprehensive approach, over 900 potential prognostic candidates were identified. Further analysis narrowed down 647 prognostic and diagnostic candidate biomarkers. The study also explored the role of the CmPn signaling network in HCC, reaffirming that its components could act as prognostic markers. Additionally, the study-utilized machine learning to discover 102 transcription factors (TFs) associated with HCC, from candidate biomarkers.ConclusionsThe findings provide insights into the molecular basis of HCC and offer potential avenues for improved diagnosis, treatment, and patient outcomes. The expanded prognostic biomarker pool aids in pinpointing HCC-specific grading and staging biomarkers, facilitating targeted therapies for improved patient outcomes and survival rates

show abstract

Performance of different biomarkers for the management of hepatocellular carcinoma

Cited by 9 publications

References 114 publications

Value of Glypican-3 as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma before and after Treatment. A Prospective Study

Value of Glypican-3 as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma before and after Treatment. A Prospective Study

Validation of Protein Biomarker Candidates for Diagnosis of HBV induced HCC

Novel hepatocellular carcinomas (HCC) Subtype-Specific Biomarkers

Contact Info

Product

Resources

About